{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T12:12:35Z","timestamp":1788696755069,"version":"build-2803163510"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,6]]},"DOI":"10.7759\/cureus.115848","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T12:07:34Z","timestamp":1788696454000},"source":"Crossref","is-referenced-by-count":0,"title":["Immunopathogenesis of Immune Checkpoint Inhibitor-Induced Myositis, Myocarditis and Myasthenia Gravis Overlap Syndrome: A Mechanistic Synthesis of a Mitochondrial Autoantigen Hypothesis"],"prefix":"10.7759","author":[{"given":"Umar","family":"Ismail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"A narrative review of immune checkpoint mechanisms and current immune checkpoint therapy","volume":"7","author":"Peng S","year":"2022","unstructured":"Peng S, Bao Y. A narrative review of immune checkpoint mechanisms and current immune checkpoint therapy. Annal of Blood. 2022, 7:33.","journal-title":"Annal of Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-01089-x","article-title":"Harnessing the biology of regulatory T cells to treat disease","volume":"24","author":"Wardell CM","year":"2025","unstructured":"Wardell CM, Boardman DA, Levings MK. Harnessing the biology of regulatory T cells to treat disease. Nat Rev Drug Discov. 2025, 24:93-111. 10.1038\/s41573-024-01089-x","journal-title":"Nat Rev Drug Discov"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen J","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al.. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022, 33:1217-38. 10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak R","year":"2021","unstructured":"Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V, Salgia R. Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist. 2021, 26:1052-61. 10.1002\/onco.13931","journal-title":"Oncologist"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14161794","article-title":"Myocarditis, myositis, and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors: a systematic review","volume":"14","author":"Lipe DN","year":"2024","unstructured":"Lipe DN, Qdaisat A, Krishnamani PP, et al.. Myocarditis, myositis, and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors: a systematic review. Diagnostics (Basel). 2024, 14:1794. 10.3390\/diagnostics14161794","journal-title":"Diagnostics (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson DB","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, et al.. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016, 375:1749-55. 10.1056\/NEJMoa1609214","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.851032","article-title":"A systematic review of the mechanisms involved in immune checkpoint inhibitors cardiotoxicity and challenges to improve clinical safety","volume":"10","author":"Rubio-Infante N","year":"2022","unstructured":"Rubio-Infante N, Ram\u00edrez-Flores YA, Castillo EC, Lozano O, Garc\u00eda-Rivas G, Torre-Amione G. A systematic review of the mechanisms involved in immune checkpoint inhibitors cardiotoxicity and challenges to improve clinical safety. Front Cell Dev Biol. 2022, 10:851032. 10.3389\/fcell.2022.851032","journal-title":"Front Cell Dev Biol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod ML","year":"2022","unstructured":"Axelrod ML, Meijers WC, Screever EM, et al.. T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis. Nature. 2022, 611:818-26. 10.1038\/s41586-022-05432-3","journal-title":"Nature"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/nri724","article-title":"Epitope spreading in immune-mediated diseases: implications for immunotherapy","volume":"2","author":"Vanderlugt CL","year":"2002","unstructured":"Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol. 2002, 2:85-95. 10.1038\/nri724","journal-title":"Nat Rev Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa H","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA, et al.. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019, 7:319. 10.1186\/s40425-019-0774-y","journal-title":"J Immunother Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200177","article-title":"Immune checkpoint inhibition-related myasthenia-myositis-myocarditis responsive to complement blockade","volume":"11","author":"Nelke C","year":"2024","unstructured":"Nelke C, Pawlitzki M, Kerkhoff R, et al.. Immune checkpoint inhibition-related myasthenia-myositis-myocarditis responsive to complement blockade. Neurol Neuroimmunol Neuroinflamm. 2024, 11:e200177. 10.1212\/NXI.0000000000200177","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-025-11095-w","article-title":"Cytokine profiling of patients with immune checkpoint inhibitor-associated myocarditis: a pilot study","volume":"52","author":"Li S","year":"2025","unstructured":"Li S, Tajiri K, Ishizuka Y, et al.. Cytokine profiling of patients with immune checkpoint inhibitor-associated myocarditis: a pilot study. Mol Biol Rep. 2025, 52:983. 10.1007\/s11033-025-11095-w","journal-title":"Mol Biol Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.056730","article-title":"Identification of pathogenic immune cell subsets associated with checkpoint inhibitor-induced myocarditis","volume":"146","author":"Zhu H","year":"2022","unstructured":"Zhu H, Galdos FX, Lee D, et al.. Identification of pathogenic immune cell subsets associated with checkpoint inhibitor-induced myocarditis. Circulation. 2022, 146:316-35. 10.1161\/CIRCULATIONAHA.121.056730","journal-title":"Circulation"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11010107","article-title":"Immunopathogenesis of immune checkpoint inhibitor induced myocarditis: insights from experimental models and treatment implications","volume":"11","author":"Wong CK","year":"2023","unstructured":"Wong CK, Lam TH, Liao SY, Lau YM, Tse HF, So BY. Immunopathogenesis of immune checkpoint inhibitor induced myocarditis: insights from experimental models and treatment implications. Biomedicines. 2023, 11:107. 10.3390\/biomedicines11010107","journal-title":"Biomedicines"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1597259","article-title":"Management of immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome: a single institution case series and literature review","volume":"16","author":"S\u00e1nchez-Camacho A","year":"2025","unstructured":"S\u00e1nchez-Camacho A, Torres-Zurita A, Gallego-L\u00f3pez L, et al.. Management of immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome: a single institution case series and literature review. Front Immunol. 2025, 16:1597259. 10.3389\/fimmu.2025.1597259","journal-title":"Front Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01464-1","article-title":"A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors","volume":"28","author":"Lessomo FY","year":"2023","unstructured":"Lessomo FY, Mandizadza OO, Mukuka C, Wang ZQ. A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors. Eur J Med Res. 2023, 28:495. 10.1186\/s40001-023-01464-1","journal-title":"Eur J Med Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1550400","article-title":"ICI-induced cardiovascular toxicity: mechanisms and immune reprogramming therapeutic strategies","volume":"16","author":"Zheng J","year":"2025","unstructured":"Zheng J, Yi Y, Tian T, Luo S, Liang X, Bai Y. ICI-induced cardiovascular toxicity: mechanisms and immune reprogramming therapeutic strategies. Front Immunol. 2025, 16:1550400. 10.3389\/fimmu.2025.1550400","journal-title":"Front Immunol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed A","year":"2020","unstructured":"Ahmed A, Tait SW. Targeting immunogenic cell death in cancer. Mol Oncol. 2020, 14:2994-3006. 10.1002\/1878-0261.12851","journal-title":"Mol Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/bies.202100029","article-title":"Tumor necrosis: a synergistic consequence of metabolic stress and inflammation","volume":"43","author":"Yee PP","year":"2021","unstructured":"Yee PP, Li W. Tumor necrosis: a synergistic consequence of metabolic stress and inflammation. Bioessays. 2021, 43:e2100029. 10.1002\/bies.202100029","journal-title":"Bioessays"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00231.2022","article-title":"Emerging mitochondrial signaling mechanisms in cardio-oncology: beyond oxidative stress","volume":"323","author":"Bikomeye JC","year":"2022","unstructured":"Bikomeye JC, Terwoord JD, Santos JH, Beyer AM. Emerging mitochondrial signaling mechanisms in cardio-oncology: beyond oxidative stress. Am J Physiol Heart Circ Physiol. 2022, 323:H702-20. 10.1152\/ajpheart.00231.2022","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-023-01002-4","article-title":"Preventing mitochondrial reverse electron transport as a strategy for cardioprotection","volume":"118","author":"Prag HA","year":"2023","unstructured":"Prag HA, Murphy MP, Krieg T. Preventing mitochondrial reverse electron transport as a strategy for cardioprotection. Basic Res Cardiol. 2023, 118:34. 10.1007\/s00395-023-01002-4","journal-title":"Basic Res Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/nature13909","article-title":"Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS","volume":"515","author":"Chouchani ET","year":"2014","unstructured":"Chouchani ET, Pell VR, Gaude E, et al.. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature. 2014, 515:431-5. 10.1038\/nature13909","journal-title":"Nature"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-394309-5.00006-7","article-title":"Cell biology of ischemia\/reperfusion injury","volume":"298","author":"Kalogeris T","year":"2012","unstructured":"Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell biology of ischemia\/reperfusion injury. Int Rev Cell Mol Biol. 2012, 298:229-317. 10.1016\/B978-0-12-394309-5.00006-7","journal-title":"Int Rev Cell Mol Biol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-022-01094-w","article-title":"Mitochondria and cell death-associated inflammation","volume":"30","author":"Vringer E","year":"2023","unstructured":"Vringer E, Tait SW. Mitochondria and cell death-associated inflammation. Cell Death Differ. 2023, 30:304-12. 10.1038\/s41418-022-01094-w","journal-title":"Cell Death Differ"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2014.11.005","article-title":"The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury","volume":"78","author":"Ong SB","year":"2015","unstructured":"Ong SB, Samangouei P, Kalkhoran SB, Hausenloy DJ. The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury. J Mol Cell Cardiol. 2015, 78:23-34. 10.1016\/j.yjmcc.2014.11.005","journal-title":"J Mol Cell Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2014.05.004","article-title":"Oxidative post-translational modifications and their involvement in the pathogenesis of autoimmune diseases","volume":"2","author":"Ryan BJ","year":"2014","unstructured":"Ryan BJ, Nissim A, Winyard PG. Oxidative post-translational modifications and their involvement in the pathogenesis of autoimmune diseases. Redox Biol. 2014, 2:715-24. 10.1016\/j.redox.2014.05.004","journal-title":"Redox Biol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05812-4","article-title":"Autoantibody and T cell responses to oxidative post-translationally modified insulin neoantigenic peptides in type 1 diabetes","volume":"66","author":"Strollo R","year":"2023","unstructured":"Strollo R, Vinci C, Man YK, et al.. Autoantibody and T cell responses to oxidative post-translationally modified insulin neoantigenic peptides in type 1 diabetes. Diabetologia. 2023, 66:132-46. 10.1007\/s00125-022-05812-4","journal-title":"Diabetologia"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2017.7382","article-title":"Oxidative modifications in tissue pathology and autoimmune disease","volume":"29","author":"Yang ML","year":"2018","unstructured":"Yang ML, Doyle HA, Clarke SG, Herold KC, Mamula MJ. Oxidative modifications in tissue pathology and autoimmune disease. Antioxid Redox Signal. 2018, 29:1415-31. 10.1089\/ars.2017.7382","journal-title":"Antioxid Redox Signal"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202501766","article-title":"Post-translational modified neoantigens in autoimmune diseases: challenges of immune tolerance","volume":"12","author":"Zhai Y","year":"2025","unstructured":"Zhai Y, Wu K, Lin Q, Cao Z, Jia Y, Zhu P. Post-translational modified neoantigens in autoimmune diseases: challenges of immune tolerance. Adv Sci (Weinh). 2025, 12:e01766. 10.1002\/advs.202501766","journal-title":"Adv Sci (Weinh)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2015.6407","article-title":"The roles of mitochondrial damage-associated molecular patterns in diseases","volume":"23","author":"Nakahira K","year":"2015","unstructured":"Nakahira K, Hisata S, Choi AM. The roles of mitochondrial damage-associated molecular patterns in diseases. Antioxid Redox Signal. 2015, 23:1329-50. 10.1089\/ars.2015.6407","journal-title":"Antioxid Redox Signal"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.15698\/cst2019.06.190","article-title":"The sensing of mitochondrial DAMPs by non-immune cells","volume":"3","author":"Rodr\u00edguez-Nuevo A","year":"2019","unstructured":"Rodr\u00edguez-Nuevo A, Zorzano A. The sensing of mitochondrial DAMPs by non-immune cells. Cell Stress. 2019, 3:195-207. 10.15698\/cst2019.06.190","journal-title":"Cell Stress"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01623-z","article-title":"T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Lozano AX","year":"2022","unstructured":"Lozano AX, Chaudhuri AA, Nene A, et al.. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nat Med. 2022, 28:353-62. 10.1038\/s41591-021-01623-z","journal-title":"Nat Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2026-015585","article-title":"Circulating B cell and T cell activation states predict clinical outcomes in melanoma and reveal dynamic immune reinvigoration with checkpoint inhibitor immunotherapy","volume":"14","author":"Booth L","year":"2026","unstructured":"Booth L, Adams R, Clifford A, et al.. Circulating B cell and T cell activation states predict clinical outcomes in melanoma and reveal dynamic immune reinvigoration with checkpoint inhibitor immunotherapy. J Immunother Cancer. 2026, 14:e015585. 10.1136\/jitc-2026-015585","journal-title":"J Immunother Cancer"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0245","article-title":"Autoantibody development under treatment with immune-checkpoint inhibitors","volume":"7","author":"de Moel EC","year":"2019","unstructured":"de Moel EC, Rozeman EA, Kapiteijn EH, et al.. Autoantibody development under treatment with immune-checkpoint inhibitors. Cancer Immunol Res. 2019, 7:6-11. 10.1158\/2326-6066.CIR-18-0245","journal-title":"Cancer Immunol Res"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2021.1314","article-title":"Defining the correlation between immune-checkpoint inhibitors-related adverse events and clinical outcomes: a narrative review","volume":"15","author":"Abdihamid O","year":"2021","unstructured":"Abdihamid O, Omar A, Rugambwa T. Defining the correlation between immune-checkpoint inhibitors-related adverse events and clinical outcomes: a narrative review. Ecancermedicalscience. 2021, 15:1314. 10.3332\/ecancer.2021.1314","journal-title":"Ecancermedicalscience"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.90106","article-title":"Immune checkpoint inhibitor-induced myositis myocarditis and myasthenia gravis (MMM) overlap syndrome in a rural district general hospital: an institutional case series involving four patients","volume":"17","author":"Ismail U","year":"2025","unstructured":"Ismail U, Both EE, Brown H. Immune checkpoint inhibitor-induced myositis myocarditis and myasthenia gravis (MMM) overlap syndrome in a rural district general hospital: an institutional case series involving four patients. Cureus. 2025, 17:e90106. 10.7759\/cureus.90106","journal-title":"Cureus"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1854723","article-title":"Immune checkpoint inhibitor-related myositis, myocarditis, and myasthenia gravis overlap syndrome: a systematic review and pooled analysis of individual cases","volume":"17","author":"Wei M","year":"2026","unstructured":"Wei M, Hu T, Yang L, Duan Y, Li Y. Immune checkpoint inhibitor-related myositis, myocarditis, and myasthenia gravis overlap syndrome: a systematic review and pooled analysis of individual cases. Front Immunol. 2026, 17:1854723. 10.3389\/fimmu.2026.1854723","journal-title":"Front Immunol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2016.08.005","article-title":"Identification of an epitope from adenine nucleotide translocator 1 that induces inflammation in heart in A\/J mice","volume":"186","author":"Basavalingappa RH","year":"2016","unstructured":"Basavalingappa RH, Massilamany C, Krishnan B, et al.. Identification of an epitope from adenine nucleotide translocator 1 that induces inflammation in heart in A\/J mice. Am J Pathol. 2016, 186:3160-75. 10.1016\/j.ajpath.2016.08.005","journal-title":"Am J Pathol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.2010.01589.x","article-title":"HLA-DR4 antigen and idiopathic dilated cardiomyopathy susceptibility: a meta-analysis involving 11,761 subjects","volume":"77","author":"Jin B","year":"2011","unstructured":"Jin B, Ni H, Geshang Q, Li Y, Shen W, Shi H. HLA-DR4 antigen and idiopathic dilated cardiomyopathy susceptibility: a meta-analysis involving 11,761 subjects. Tissue Antigens. 2011, 77:107-11. 10.1111\/j.1399-0039.2010.01589.x","journal-title":"Tissue Antigens"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a112335","article-title":"Causes","volume":"104","author":"Rothman KJ","year":"1976","unstructured":"Rothman KJ. Causes. Am J Epidemiol. 1976, 104:587-92. 10.1093\/oxfordjournals.aje.a112335","journal-title":"Am J Epidemiol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3390\/antib5010002","article-title":"Autoantibodies in SLE: specificities, isotypes and receptors","volume":"5","author":"Dema B","year":"2016","unstructured":"Dema B, Charles N. Autoantibodies in SLE: specificities, isotypes and receptors. Antibodies (Basel). 2016, 5:2. 10.3390\/antib5010002","journal-title":"Antibodies (Basel)"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.2478\/rir-2023-0003","article-title":"Pathogenesis of anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"4","author":"Sun XJ","year":"2023","unstructured":"Sun XJ, Li ZY, Chen M. Pathogenesis of anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatol Immunol Res. 2023, 4:11-21. 10.2478\/rir-2023-0003","journal-title":"Rheumatol Immunol Res"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.177","article-title":"Branched chain \u03b1-ketoacid dehydrogenase kinase 111-130, a T cell epitope that induces both autoimmune myocarditis and hepatitis in A\/J mice","volume":"5","author":"Krishnan B","year":"2017","unstructured":"Krishnan B, Massilamany C, Basavalingappa RH, et al.. Branched chain \u03b1-ketoacid dehydrogenase kinase 111-130, a T cell epitope that induces both autoimmune myocarditis and hepatitis in A\/J mice. Immun Inflamm Dis. 2017, 5:421-34. 10.1002\/iid3.177","journal-title":"Immun Inflamm Dis"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.06.004","article-title":"Inflammatory myopathy associated with anti-mitochondrial antibodies: a distinct phenotype with cardiac involvement","volume":"47","author":"Albayda J","year":"2018","unstructured":"Albayda J, Khan A, Casciola-Rosen L, Corse AM, Paik JJ, Christopher-Stine L. Inflammatory myopathy associated with anti-mitochondrial antibodies: a distinct phenotype with cardiac involvement. Semin Arthritis Rheum. 2018, 47:552-6. 10.1016\/j.semarthrit.2017.06.004","journal-title":"Semin Arthritis Rheum"},{"key":"ref45","article-title":"Insights into mitochondrial protein import studied by cryoET","author":"Gold V","year":"2016","unstructured":"Gold V, Chro\u015bcicki P, Br\u0105goszewski P, Chacinska A . Insights into mitochondrial protein import studied by cryoET. European Microscopy Congress: Proceedings. 2016. 276-7."},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1038\/nature14859","article-title":"A cytosolic network suppressing mitochondria-mediated proteostatic stress and cell death","volume":"524","author":"Wang X","year":"2015","unstructured":"Wang X, Chen XJ. A cytosolic network suppressing mitochondria-mediated proteostatic stress and cell death. Nature. 2015, 524:481-4. 10.1038\/nature14859","journal-title":"Nature"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.17.1.739","article-title":"Degradation of cell proteins and the generation of MHC class I-presented peptides","volume":"17","author":"Rock KL","year":"1999","unstructured":"Rock KL, Goldberg AL. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol. 1999, 17:739-79. 10.1146\/annurev.immunol.17.1.739","journal-title":"Annu Rev Immunol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.05.039","article-title":"Parkinson's disease-related proteins PINK1 and parkin repress mitochondrial antigen presentation","volume":"166","author":"Matheoud D","year":"2016","unstructured":"Matheoud D, Sugiura A, Bellemare-Pelletier A, et al.. Parkinson's disease-related proteins PINK1 and parkin repress mitochondrial antigen presentation. Cell. 2016, 166:314-27. 10.1016\/j.cell.2016.05.039","journal-title":"Cell"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1374796","article-title":"Mitochondrial extracellular vesicles, autoimmunity and myocarditis","volume":"15","author":"Di Florio DN","year":"2024","unstructured":"Di Florio DN, Beetler DJ, McCabe EJ, Sin J, Ikezu T, Fairweather D. Mitochondrial extracellular vesicles, autoimmunity and myocarditis. Front Immunol. 2024, 15:1374796. 10.3389\/fimmu.2024.1374796","journal-title":"Front Immunol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20122149","article-title":"Macroautophagy substrates are loaded onto MHC class II of medullary thymic epithelial cells for central tolerance","volume":"210","author":"Aichinger M","year":"2013","unstructured":"Aichinger M, Wu C, Nedjic J, Klein L. Macroautophagy substrates are loaded onto MHC class II of medullary thymic epithelial cells for central tolerance. J Exp Med. 2013, 210:287-300. 10.1084\/jem.20122149","journal-title":"J Exp Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1038\/nature08780","article-title":"Circulating mitochondrial DAMPs cause inflammatory responses to injury","volume":"464","author":"Zhang Q","year":"2010","unstructured":"Zhang Q, Raoof M, Chen Y, et al.. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010, 464:104-7. 10.1038\/nature08780","journal-title":"Nature"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2026.104032","article-title":"Emerging frontiers in the mitochondrial regulation of dendritic cell biology","volume":"90","author":"Chen B","year":"2026","unstructured":"Chen B, Mayer JU. Emerging frontiers in the mitochondrial regulation of dendritic cell biology. Redox Biol. 2026, 90:104032. 10.1016\/j.redox.2026.104032","journal-title":"Redox Biol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18091442","article-title":"Danger or salvation? The role of DAMPs in cancer therapy","volume":"18","author":"Vedunova AA","year":"2026","unstructured":"Vedunova AA, Guryev EL, Gudkov SV, Mishchenko TA, Vedunova MV. Danger or salvation? The role of DAMPs in cancer therapy. Cancers (Basel). 2026, 18:1442. 10.3390\/cancers18091442","journal-title":"Cancers (Basel)"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12630","article-title":"Macrophages transfer antigens to dendritic cells by releasing exosomes containing dead-cell-associated antigens partially through a ceramide-dependent pathway to enhance CD4(+) T-cell responses","volume":"149","author":"Xu Y","year":"2016","unstructured":"Xu Y, Liu Y, Yang C, et al.. Macrophages transfer antigens to dendritic cells by releasing exosomes containing dead-cell-associated antigens partially through a ceramide-dependent pathway to enhance CD4(+) T-cell responses. Immunology. 2016, 149:157-71. 10.1111\/imm.12630","journal-title":"Immunology"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.crc-22-0052","article-title":"Neoantigen presentation and IFN\u03b3 signaling on the same tumor-associated macrophage are necessary for CD4 T cell-mediated antitumor activity in mice","volume":"2","author":"Perez-Diez A","year":"2022","unstructured":"Perez-Diez A, Liu X, Matzinger P. Neoantigen presentation and IFN\u03b3 signaling on the same tumor-associated macrophage are necessary for CD4 T cell-mediated antitumor activity in mice. Cancer Res Commun. 2022, 2:316-29. 10.1158\/2767-9764.crc-22-0052","journal-title":"Cancer Res Commun"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112732","article-title":"Tumor-specific CD4 T\u00a0cells instruct monocyte fate in pancreatic ductal adenocarcinoma","volume":"42","author":"Patterson MT","year":"2023","unstructured":"Patterson MT, Burrack AL, Xu Y, et al.. Tumor-specific CD4 T\u00a0cells instruct monocyte fate in pancreatic ductal adenocarcinoma. Cell Rep. 2023, 42:112732. 10.1016\/j.celrep.2023.112732","journal-title":"Cell Rep"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202403044","article-title":"Surface molecularly engineered mitochondria conduct immunophenotype repolarization of tumor-associated macrophages to potentiate cancer immunotherapy","volume":"11","author":"Zhang CJ","year":"2024","unstructured":"Zhang CJ, Li JM, Xu D, et al.. Surface molecularly engineered mitochondria conduct immunophenotype repolarization of tumor-associated macrophages to potentiate cancer immunotherapy. Adv Sci (Weinh). 2024, 11:e2403044. 10.1002\/advs.202403044","journal-title":"Adv Sci (Weinh)"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1177\/088307389400900102","article-title":"Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): current concepts","volume":"9","author":"Hirano M","year":"1994","unstructured":"Hirano M, Pavlakis SG. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): current concepts. J Child Neurol. 1994, 9:4-13. 10.1177\/088307389400900102","journal-title":"J Child Neurol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1002\/cld.1133","article-title":"Mitochondrial hepatopathies","volume":"18","author":"Alharbi H","year":"2021","unstructured":"Alharbi H, Priestley JR, Wilkins BJ, Ganetzky RD. Mitochondrial hepatopathies. Clin Liver Dis (Hoboken). 2021, 18:243-50. 10.1002\/cld.1133","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3780288","article-title":"Mitochondrial dna depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors","volume":"81","author":"Lewis W","year":"2001","unstructured":"Lewis W, Copeland WC, Day BJ. Mitochondrial dna depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors. Lab Invest. 2001, 81:777-90. 10.1038\/labinvest.3780288","journal-title":"Lab Invest"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus NE","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJ. Myasthenia gravis. Nat Rev Dis Primers. 2019, 5:30. 10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Primers"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1006\/clin.1998.4536","article-title":"Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients","volume":"87","author":"Gunji K","year":"1998","unstructured":"Gunji K, Skolnick C, Bednarczuk T, et al.. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients. Clin Immunol Immunopathol. 1998, 87:276-81. 10.1006\/clin.1998.4536","journal-title":"Clin Immunol Immunopathol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.carpath.2020.107211","article-title":"Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy","volume":"47","author":"Balanescu DV","year":"2020","unstructured":"Balanescu DV, Donisan T, Palaskas N, et al.. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy. Cardiovasc Pathol. 2020, 47:107211. 10.1016\/j.carpath.2020.107211","journal-title":"Cardiovasc Pathol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem JE","year":"2019","unstructured":"Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, Kerneis M. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med. 2019, 380:2377-9. 10.1056\/NEJMc1901677","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/398537-immunopathogenesis-of-immune-checkpoint-inhibitor-induced-myositis-myocarditis-and-myasthenia-gravis-overlap-syndrome-a-mechanistic-synthesis-of-a-mitochondrial-autoantigen-hypothesis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T12:07:35Z","timestamp":1788696455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/398537-immunopathogenesis-of-immune-checkpoint-inhibitor-induced-myositis-myocarditis-and-myasthenia-gravis-overlap-syndrome-a-mechanistic-synthesis-of-a-mitochondrial-autoantigen-hypothesis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,6]]},"references-count":64,"URL":"https:\/\/doi.org\/10.7759\/cureus.115848","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,6]]}}}